Medpace Holdings, Inc. (MEDP) is the 12th largest of 98 Pharma Services companies by market capitalisation, at 16.40 Bn, behind Viatris at 18.96 Bn. It trades on a P/E of 35.35, 40% above the peer median of 25.34. The table below compares all 98 on 7 financial metrics, including companies with a secondary business in the group.
| # | Symbol | Company | Industry | Mkt Cap | Price | Chg % | 1Y | P/E | P/S | Enterprise Value |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TMO 2nd | Thermo Fisher Scientific | Contract Research | 225.55 Bn | 610.00 | +1.14% | +24.13% | 34.33 | 5.22 | 237.61 Bn |
| 2 | PFE 2nd | Pfizer | Contract Manufacturing | 157.82 Bn | 27.69 | +0.14% | +11.38% | 35.88 | 2.46 | 145.02 Bn |
| 3 | TEVA 2nd | Teva Pharmaceutical Industries | Contract Manufacturing | 43.23 Bn | 37.10 | +2.06% | +86.53% | 64.54 | 2.59 | 41.27 Bn |
| 4 | IQV | Iqvia Holdings | Contract Research | 43.09 Bn | 261.78 | +1.74% | +37.28% | 33.88 | 2.63 | 42.64 Bn |
| 5 | ZTS 2nd | Zoetis | Contract Manufacturing | 30.22 Bn | 72.97 | +0.12% | -51.16% | 9.34 | 3.21 | 28.90 Bn |
| 6 | LH 2nd | Labcorp Holdings | Contract Research | 25.22 Bn | 311.69 | +1.52% | +14.20% | 26.42 | 1.85 | 26.37 Bn |
| 7 | WST 2nd | West Pharmaceutical Services | Contract Manufacturing | 24.36 Bn | 346.06 | +0.46% | +35.59% | 46.80 | 7.73 | 25.28 Bn |
| 8 | IFF 2nd | International Flavors & Fragrances | Contract Manufacturing | 21.35 Bn | 83.61 | -0.55% | +26.01% | 73.69 | 2.16 | 20.95 Bn |
| 9 | GH 2nd | Guardant Health | Contract Research | 21.03 Bn | 157.38 | -1.04% | +178.20% | -51.10 | 19.58 | 22.12 Bn |
| 10 | STE 2nd | Steris | Contract Manufacturing | 20.55 Bn | 210.73 | -0.80% | -16.52% | 25.34 | 3.39 | 19.99 Bn |
| 11 | VTRS 2nd | Viatris | Contract Manufacturing | 18.96 Bn | 16.51 | +0.79% | +61.23% | -48.19 | 1.34 | 18.91 Bn |
| 12 | MEDP | Medpace Holdings | Contract Research | 16.40 Bn | 587.52 | +0.75% | +23.25% | 35.35 | 6.24 | 16.87 Bn |
| 13 | LDOS 2nd | Leidos Holdings | Contract Research | 16.17 Bn | 128.86 | -0.49% | -28.56% | 11.68 | 0.92 | 15.55 Bn |
| 14 | CRL | Charles River Laboratories International | Contract Research | 13.28 Bn | 278.27 | +1.88% | +81.56% | -55.23 | 3.28 | 12.94 Bn |
| 15 | ICLR | Icon | Contract Research | 12.96 Bn | 169.31 | +2.18% | +2.34% | 17.54 | 1.65 | 12.72 Bn |
| 16 | DVA 2nd | Davita | Contract Research | 11.61 Bn | 181.48 | +0.03% | +37.21% | 10.80 | 0.90 | 11.88 Bn |
| 17 | TEM 2nd | Tempus AI | Contract Research | 10.34 Bn | 59.01 | +0.46% | -33.53% | -50.67 | 8.79 | 11.77 Bn |
| 18 | RDY 2nd | Dr Reddys Laboratories | Contract Manufacturing | 9.92 Bn | 11.89 | +1.45% | -19.28% | 770.28 | 2.65 | 9.55 Bn |
| 19 | PODD 2nd | Insulet | Contract Manufacturing | 9.15 Bn | 131.96 | -2.02% | -60.91% | 25.95 | 3.19 | 9.21 Bn |
| 20 | IONS 2nd | Ionis Pharmaceuticals | Contract Manufacturing | 8.98 Bn | 54.21 | -2.59% | -15.35% | -35.16 | 8.54 | 5.41 Bn |
| 21 | TWST 2nd | Twist Bioscience | Contract Research | 7.97 Bn | 127.22 | +0.29% | +426.57% | -65.32 | 20.68 | 8.76 Bn |
| 22 | ALKS 2nd | Alkermes | Contract Manufacturing | 7.70 Bn | 45.97 | -0.30% | +70.70% | 116.15 | 4.61 | 7.02 Bn |
| 23 | CAI 2nd | Caris Life Sciences | Contract Research | 6.88 Bn | 24.34 | +1.25% | -27.13% | 76.17 | 8.09 | 7.22 Bn |
| 24 | LNTH 2nd | Lantheus Holdings | Contract Manufacturing | 6.54 Bn | 100.25 | -0.14% | +82.31% | 23.81 | 4.21 | 5.96 Bn |
| 25 | LQDA 2nd | Liquidia | Contract Manufacturing | 5.95 Bn | 66.74 | -1.64% | +144.56% | 43.89 | 13.49 | 5.80 Bn |
Medpace Holdings, Inc. (MEDP) is compared with 98 US-listed companies in the Pharma Services industry group, of which 16 have it as their primary business and 82 run a substantial Pharma Services business alongside something else.
Peers are every company that BQ-MICS, our own multi-industry classification system, places in the same industry group as Medpace Holdings, Inc.. Unlike a single-label scheme, BQ-MICS assigns each company a primary industry and any secondary industries it genuinely operates in, and records the reasoning behind every assignment. Tap the info icon beside any ticker to read it.
It marks a secondary match: the company operates a real business in this industry group, but it is not its largest. Tick "Primary business only" above the table to compare against pure plays alone.
Prices, market caps and valuation figures refresh with each session's close. The classification itself is reviewed whenever a company's filings change what it does, such as a new segment, a disposal or an acquisition.
Yes. Use Edit Columns above the table to add any of 1,000+ financial metrics and ratios to the comparison, and Download Data to export it.